Printer Friendly

CardioComm receives FDA clearance for hand-held heart rhythm monitor.

M2 PHARMA-January 20, 2012-CardioComm receives FDA clearance for hand-held heart rhythm monitor(C)2012 M2 COMMUNICATIONS

20 January 2012 - CardioComm Solutions Inc (CVE:EKG), a US-based company specialising in the development of software and hardware related to personal heart arrhythmia monitoring systems, received the green light from the US Food and Drug Administration (FDA) to begin over-the-counter sales of its hand-held heart rhythm monitor known as the HeartCheck Pen Handheld ECG.

The FDA approval also covers CardioComm Solutions' GEMS (Global ECG Management System) Home software, which enables the HeartCheck Pen to be connected to a personal computer to upload data on the patient's heart rhythm to CardioComm Solutions' C4 medical call service telemedicine group for review by a physician.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 20, 2012
Previous Article:J&J agrees to pay USD158m to settle Risperdal case in Texas.
Next Article:NuPathe gets allowance of additional US patent application for migraine patch.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters